Treace(US:TMCI) Globenewswire·2025-08-07 20:05Core Insights - Treace Medical Concepts, Inc. has announced the full market release of three new bunion technologies, aiming to enhance surgical treatment options for bunions and related midfoot deformities [1][3] - The company reported a revenue increase of 7% in Q2 2025 compared to the same period in 2024, indicating strong demand for its expanded portfolio of 3D bunion solutions [4][8] Financial Performance - Revenue for Q2 2025 was $47.4 million, up from $44.5 million in Q2 2024, reflecting a 7% growth [4] - Gross profit for Q2 2025 was $37.8 million, with a gross margin of 79.7%, slightly down from 80.2% in Q2 2024 [4] - Total operating expenses decreased by 4.1% to $54.7 million in Q2 2025 from $57.1 million in Q2 2024 [5] - The net loss for Q2 2025 was $(17.4) million, or $(0.28) per share, an improvement from $(21.2) million, or $(0.34) per share, in Q2 2024 [6] - Adjusted EBITDA loss improved by 58% to $(3.6) million in Q2 2025 compared to $(8.7) million in Q2 2024 [6][8] Liquidity and Outlook - As of June 30, 2025, the company had total liquidity of $90.7 million, consisting of $69.3 million in cash and marketable securities and $21.4 million available under a revolving loan facility [7] - The company reaffirmed its full-year 2025 revenue guidance of $224 million to $230 million, representing a growth of 7% to 10% compared to 2024 [8] Product Development and Market Position - The company has expanded its bunion technology portfolio with the full market release of the Nanoplasty and Percuplasty™ systems, as well as the SpeedMTP MTP Fusion System [8] - Treace's patent portfolio has grown to 117 granted patents and 163 pending applications, enhancing its competitive position in the market [8] Strategic Initiatives - The CEO expressed confidence that the new technologies, along with existing systems like Lapiplasty and Adductoplasty, will establish Treace as a leading provider of surgical bunion technology [3]